India’s GLP-1 market stabilises as generic semaglutide boom fades
GLP-1 sales reached Rs 247 crore in August, marginally above July’s Rs 245 crore. Injectable semaglutide grew to Rs 76 crore, while Eli Lilly’s Mounjaro retained category leadership with Rs 1,256 crore in 12-month revenue and a 54% share of the Rs 2,333-crore market.
What happened
India’s GLP-1 market is stabilising after semaglutide generics spurred an early-year surge. Injectable demand is rising, while Eli Lilly’s Mounjaro remains the
Key facts
- GLP-1 monthly sales: Rs 247 crore in August vs Rs 245 crore in July
- GLP-1 monthly sales: Rs 218 crore in April, Rs 236 crore in May and Rs 180 crore in March
- Injectable semaglutide sales: Rs 76 crore in August vs Rs 73 crore in July
- Oral semaglutide sales: Rs 29 crore vs Rs 31 crore
- 33 generic injectable brands; 11 account for 80% of generic unit sales
- Mounjaro 12-month revenue: Rs 1,256 crore, or 54% of the Rs 2,333-crore domestic GLP-1 market
- Tirzepatide monthly sales: Rs 142 crore in August vs Rs 114 crore in March
- Domestic pharma market: Rs 2.59 lakh crore over 12 months to August, up 10.7% in value
Why this matters
Partnership and acquisition opportunities increasingly favor differentiated GLP-1 brands, distribution capabilities, and patient-support platforms over undifferentiated generic semaglutide exposure.
What to watch
- Monthly molecule-level sales: whether tirzepatide continues to outgrow the total GLP-1 market.
- Generic semaglutide price reductions, new marketer launches and pharmacy margin changes.
- Prescription repeat rates and treatment discontinuation after the first three to six months.
- Insurance, employer-benefit or corporate wellness coverage announcements for obesity treatment.
- Supply constraints, cold-chain disruptions or regulatory actions affecting compounded/generic GLP-1 products.
- Expansion of obesity clinics and digital-care providers that can redirect prescription volume to preferred pharmacy partners.
- Prioritize Mounjaro availability, cold-chain reliability and refill retention at high-volume urban pharmacy locations.
- Create a distinct value-tier semaglutide assortment and communication strategy rather than competing head-on with premium tirzepatide on price.
- Expand pharmacist-led onboarding, side-effect guidance and adherence reminders to protect recurring revenue and reduce early drop-off.
- Bundle GLP-1 dispensing with protein, glucose-monitoring, nutrition and metabolic-health services where compliant with local regulations.
- Tighten inventory forecasting by molecule and pack size; avoid broad generic semaglutide stock build until monthly sell-through resumes.